文献速递真菌感染细菌感染、耐药与抗菌药物

艾沙康唑对念珠菌临床分离株体外活性高但存在拖尾效应

Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect.
PubMed 文献 · Clin Microbiol Infect · 2020-07-23

该研究对2007年1月至2017年9月住院患者血标本中761株经分子鉴定的念珠菌,按EUCAST E.Def 7.3.1方法测定艾沙康唑MIC并评估拖尾效应。结果显示艾沙康唑对念珠菌体外活性高,尤其对白念珠菌,但拖尾效应常见,以光滑念珠菌为著。

要点

  • 艾沙康唑对血源念珠菌分离株体外活性高,白念珠菌最高。
  • 拖尾效应总体平均12.9%,光滑念珠菌、白念珠菌和热带念珠菌更明显。
  • 光滑念珠菌和克柔念珠菌MIC几何均值显著高于白念珠菌。

核心结论

  • 艾沙康唑对念珠菌属体外活性高,尤其对白念珠菌。
  • 使用EUCAST E.Def 7.3.1方法时艾沙康唑常见拖尾效应,以光滑念珠菌为著。

研究设计与样本

  • 研究纳入2007年1月至2017年9月742例住院患者血标本中761株经分子鉴定的念珠菌分离株。
  • 按EUCAST E.Def 7.3.1方法测定艾沙康唑体外敏感性并评估拖尾效应。

主要发现

  • 白念珠菌敏感性最高,其次为近平滑念珠菌和热带念珠菌,几何均值MIC分别为0.003与0.005/0.006(P<0.001)。
  • 光滑念珠菌和克柔念珠菌MIC值显著更高,几何均值MIC分别为0.094与0.093。
  • 除白念珠菌外,艾沙康唑MIC分布未在最低测试浓度处截断。
  • 拖尾效应总体平均百分比为12.9%,光滑念珠菌、白念珠菌和热带念珠菌高于近平滑念珠菌和非念珠菌酵母(P<0.001)。
  • 非野生型白念珠菌(将重度拖尾株视为野生型)、近平滑念珠菌和光滑念珠菌的百分比分别为0.56%(2/355)、1.5%(3/200)和4.65%(4/86)。

关键数值与推荐

  • 白念珠菌几何均值MIC为0.003,近平滑念珠菌和热带念珠菌为0.005/0.006(P<0.001)。
  • 光滑念珠菌和克柔念珠菌几何均值MIC分别为0.094和0.093。
  • 拖尾效应总体平均百分比为12.9%。
  • 非野生型白念珠菌、近平滑念珠菌和光滑念珠菌百分比分别为0.56%(2/355)、1.5%(3/200)和4.65%(4/86)。

临床怎么用

  • 艾沙康唑对血源念珠菌尤其是白念珠菌体外活性高,可作为念珠菌感染治疗参考。
  • 解读艾沙康唑MIC时需注意拖尾效应,尤其光滑念珠菌,避免误判为敏感。

局限性

  • 研究仅评估体外敏感性,未报告临床疗效数据。
  • 拖尾效应判读标准中将重度拖尾株视为野生型,可能影响非野生型百分比解释。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Isavuconazole is a triazole previously shown to have potent in vitro activity against Aspergillus spp., Mucorales, and Candida spp. Unlike for other azoles, it is unclear if isavuconazole may induce a trailing effect. We studied isavuconazole MICs for a large collection of Candida isolates from blood samples and determined the extent of the trailing effect when using the EUCAST Edef 7.3.1 method. METHODS: 761 molecularly identified Candida isolates from blood samples of 742 patients admitted to the hospital (January 2007 to September 2017) were evaluated and further tested for in vitro susceptibility to isavuconazole following the EUCAST E.Def 7.3.1 test method. RESULTS: C. albicans showed the highest susceptibility, followed by C. parapsilosis and C. tropicalis (geometric mean MIC 0.003 vs 0.005/0.006, respectively; P < 0.001). In contrast, C. glabrata, and C. krusei had significantly higher MIC values (geometric mean MIC 0.094 vs 0.093, respectively). Isavuconazole MIC distributions were not truncated at the lowest concentration tested, except for C. albicans. Overall, the mean percentage of trailing was 12.9% but differences among species were observed: C. glabrata, C. albicans, and C. tropicalis exhibited higher trailing in comparison to C. parapsilosis and non-Candida yeasts (P < 0.001). The percentage of non-wild-type C. albicans (considering the heavy trailer isolates as wild-type), C. parapsilosis and C. glabrata isolates were 0.56% (2/355), 1.5% (3/200), and 4.65% (4/86), respectively. CONCLUSIONS: Isavuconazole showed high in vitro activity against Candida spp., particularly against C. albicans. Trailing effect is commonly observed with isavuconazole, particularly with C. glabrata.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Marcos-Zambrano LJ, Gómez A, Sánchez-Carrillo C, et al. Isavuconazole is highly active in vitro against Candida species isolates but shows trailing effect. Clin Microbiol Infect. 2020. PMID: 32712246. doi:10.1016/j.cmi.2020.07.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。